¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Blood Group Antigens"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
¿µ¹® blood ÇÑ±Û Ç÷¾×, ÇÇ
¼³¸í   
  ¼øÈ¯±â, Áï ½ÉÀå°ú Ç÷°ü ¾ÈÀ» ¼øÈ¯Çϴ À¯µ¿¼ºÀÇ Á¶Á÷À» ¸»ÇÑ´Ù. Ç÷¾×Àº Àüü Ã¼ÁßÀÇ ¾à 8%¸¦ Â÷ÁöÇϸç, ºñÁßÀº 1,056~1,059, Á¡µµ´Â ¾à 4.5, pH´Â 7.4ÀÌ´Ù. Ç÷¾×Àº ¾×ü¼ººÐÀΠÇ÷Àå°ú °Å±â¿¡ ¶°µ¹°í Àִ ¼¼Æ÷¼ººÐÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. Ç÷ÀåÀº Àüü Ç÷¾×ÀÇ 55%¸¦ Â÷ÁöÇϸ砼öºÐ, ´Ü¹éÁú, Ç÷´ç, Áö¹æÁú, ¹«±â¿°·ù, Áú¼ÒÈ­ÇÕ¹°·Î ÀÌ·ç¾îÁø´Ù. ¼¼Æ÷¼ººÐÀº Àüü Ç÷¾×ÀÇ 45%¸¦ Â÷ÁöÇϸç ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇÀ¸·Î ÀÌ·ç¾îÁ® ÀÖ´Ù. Ç÷¾×ÀÇ ÁÖ¿ä ±â´ÉÀº Àü½Å Á¶Á÷À¸·Î »ê¼Ò¿Í ¿µ¾çºÐ °°Àº ÇÊ¿äÇÑ ¹°ÁúÀ» ¿î¹ÝÇϸ砺ÒÇÊ¿äÇÑ ¹°ÁúÀ» ¹è¼³±â°üÀ¸·Î ¿î¹ÝÇϴ ÀÏÀÌ´Ù. ±× ¹Û¿¡ »ýü¿¡ Çطο°ÁúÀ̳ª ¼¼±ÕÀ» Á¦°ÅÇϰí, ³»ºÎȯ°æÀÇ Çâ»ó¼ºÀ» À¯ÁöÇϸç, Ã¼¿ÂÀ¯Áö¿Í »ýü ¹æ¾î ±â´ÉÀ» ÇÑ´Ù. »ç¶÷ÀÇ Ç÷¾×Àº ¿©·¯ °¡Áö ¼¼Æ÷ Ç÷±¸¿Í ±× ¼¼Æ÷¸¦ Æ÷ÇÔÇϴ ¸¼Àº ¾×üÀΠÇ÷Àå·Î ±¸¼ºµÇ¾î ÀÖ´Ù. Ç÷±¸´Â ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ÀûÇ÷±¸´Â ºÓÀº »öÀ» ¶ì´Â ¼¼Æ÷·Î »ê¼Ò¸¦ ¸öÀÇ Á¶Á÷À¸·Î ¿î¹ÝÇϴ ¿ªÇÒÀ» ÇÑ´Ù. Ç÷¼ÒÆÇÀº Ç÷¾×ÀÀ°í¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϴ ¼¼Æ÷ÀÌ´Ù.
  
  ¹éÇ÷±¸´Â Àΰ£ÀÇ ¸é¿ª¿¡ °ü°èÇϴ ¼¼Æ÷À̸砱¸Ã¼ÀûÀ¸·Î ´ÙÀ½°ú °°Àº ¼¼Æ÷µéÀÌ ÀÖ´Ù.
  
  1.°ú¸³±¸(granulocyte): °ú¸³±¸¶õ ¹éÇ÷±¸ÀÇ 60%¸¦ Â÷ÁöÇϸç, ¼¼Æ÷¼Ó¿¡ Æ¯ÀÌÇÑ °ú¸³À» °¡Áö°í Àִ ¼¼Æ÷À̸ç, ´ÙÀ½°ú °°Àº 3°¡ÁöÀÇ ¼¼Æ÷°¡ À̰÷¿¡ Æ÷ÇÔÀÌ µÈ´Ù.
  
    -È£¿°±â±¸(basophil): ¿°±â¼º¿°»ö¾à¿¡ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö°í ÀÖ´Ù. ºÒ±ÔÄ¢ÇÑ ¸ð¾çÀÇ ¼¼Æ÷·Î Çª¸¥ »öÀ» ¶ì´Â °ú¸³ÀÌ ³Ê¹« ¸¹ÀÌ À־ ÇÙÀÌ Àß º¸ÀÌÁö ¾Ê´Â´Ù.
  
    -È£»ê±¸(eosinophil): »ê¼º¿°»ö¾à¿¡ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö°í ÀÖ°í, ´ë°³ ±â»ýÃæÀÇ °¨¿°À̳ª, ¾Ë·¯Áö¿¡¼­ ¸¹ÀÌ Áõ°¡ÇÑ´Ù. ´ë°³ 2°³ÀÇ ÇÙÀ» °¡Áö°í ÀÖÀ¸¸ç ÇÙ»çÀÌ¿¡ °¡´Â ½Ç°°Àº °ÍÀ¸·Î À̾îÁ® ÀÖ´Ù.
  
    -È£Áß±¸(neutrophil): »ê¼º¿°»ö¾àÀ̳ª ¿°±â¼º¿°»ö¾à¿¡ ÀÇÇÏ¿© ¸ðµÎ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö´Â ¼¼Æ÷·Î ´ë°³ 3°³ÀÇ ÇÙÀ» °¡Áø´Ù. ±×¸®°í ÇÙ»çÀÌ¿¡ °¡´Â ½Ç°°Àº ±¸Á¶¹°ÀÌ À־ ÇÙÀ» ¼­·Î À̾îÁÖ°í ÀÖ´Ù.
  
  2.´ÜÇÙ±¸(monocyte): ´Ù°¢Çü¸ð¾çÀ» °¡Áø ¼¼Æ÷·Î °ú¸³À» °¡Áö°í ÀÖÁö ¾Ê´Ù. ¿Ü°è·ÎºÎÅÍ µé¾î¿Â ¹°ÁúÀ» Àâ¾Æ¸Ô´Â ¿ªÇÒ°ú ±×°Í¿¡ ´ëÇÑ Á¤º¸¸¦ Á¦°øÇϴ ¿ªÇÒÀ» ÇÏ¿© ¸é¿ª¿¡ °ü°èÇÑ´Ù. À̰ÍÀÌ Ç÷¾× Áß¿¡ Á¸ÀçÇÏÁö ¾Ê°í Á¶Á÷¿¡ °íÁ¤µÇ¾î Àִ °æ¿ì¿¡ À̰ÍÀ» Å«Æ÷½Ä¼¼Æ÷¶ó°í ÇÑ´Ù.
  
  3.¸²ÇÁ±¸(lymphocyte): ÀÛÀº ¿øÇüÀÇ ¼¼Æ÷·Î ¸é¿ª¿¡ ÁßÃßÀûÀΠ¿ªÇÒÀ» ÇÑ´Ù.
¿µ¹® blood gas ÇÑ±Û Ç÷¾×°¡½º, Ç÷¾×±âü
¼³¸í   
  Ç÷¾× ¼Ó¿¡ ¿ëÇØµÇ¾î Àִ »ê¼Ò, ÀÌ»êȭź¼Ò, Áú¼Ò µûÀ§ÀÇ ±âü. Ç÷¾×ÀÇ »ê¼º-¿°±â¼ºÀÇ Á¤µµ¸¦ ÃøÁ¤ÇÒ ¼ö ÀÖ´Ù.
¿µ¹® blood test ÇÑ±Û Ç÷¾×°Ë»ç
¼³¸í   
  Ç÷¾×ÇüÀ̳ª Áúº´ À¯¹« µûÀ§¸¦ ¾Ë±â À§ÇÏ¿© ÇǸ¦ »Ì¾Æ ÇàÇϴ °Ë»ç. ¸ö ÀüüÀÇ Àå±â³ª Á¶Á÷¿¡ º´ÅͰ¡ ÀÖÀ¸¸é À̵頼ººÐ¿¡ º¯È­°¡ ÀÖ°Ô µÇ¾î Áø´Ü¿¡ Å« µµ¿òÀ» ÁØ´Ù.
¿µ¹® blood-brain barrier ÇÑ±Û Ç÷¾×³úÀ庮
¼³¸í   
  Ç÷¾×À¸·ÎºÎÅÍ ³ú·Î´Â ÁöÁú¿ëÇØ¼ºÀÌ ³ôÀº ¾à¹°¹Û¿¡ ÀÌÇàµÇÁö ¾Ê´Â´Ù. ¼ö¿ë¼ºÀÇ ¾à¹°À» ³ú·Î ÀÌÇàµÇÁö ¾Ê°Ô Çϰí Àִ °ÍÀÌ Ç÷¾×³úÀ庮À̸砳úÀÇ ¸ð¼¼Ç÷°ü ³»ÇǼ¼Æ÷, ¸ð¼¼Ç÷°ü ÁÖÀ§ÀÇ ¼¼Æ÷°¡ À庮ÀÌ µÇ°í ÀÖ´Ù. ¹°Áú±³È¯Àº ¼öµ¿È®»ê¿¡ ÀÇÇØ ÀÌ·ç¾îÁöÁö¸¸, ³úÀÇ »ý¸®Àû È°µ¿¿¡ ÇÊ¿äÇÑ ¹°ÁúÀº ÀÌ¿ÂÇüÀ̶󵵠´ãü¸¦ ÅëÇØ ÀÌÇàµÈ´Ù.
¿µ¹® blood volume ÇÑ±Û Ç÷¾×·®
¼³¸í   
  Ã¼³»¿¡ Á¸ÀçÇϴ Ç÷¾×ÀÇ ÃÑ·®À¸·Î¼­, º¸Åë ¸®ÅÍ ¶Ç´Â Ã¼Áß 1kg¿¡ ´ëÇÏ¿© ¸®Åͼö·Î Ç¥½ÃÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • group-specific antigen
    ¹«¸®Æ¯ÀÌÇ׿ø, ±ºÆ¯ÀÌÇ׿ø
  • high risk group
    °íÀ§Ç豺
  • haptenic group
    ºÒ¿ÏÀüÇ׿ø±º, ÇÕÅÙ±º
  • linkage group
    ¿¬°ü±º
  • low risk group
    ÀúÀ§Ç豺
  • methyl group
    ¸ÞÆ¿±â
  • osmophore group
    ¹ßÇâ´Ü(Û¡úÅÓ¥)
  • prosthetic group
    1. º¸°áºÐÀÚ´Ü 2. º¸°á¿øÀÚ´Ü
  • soluble group
    °¡¿ëÇØ±º
  • self-help group
    ÀÚ°¡µµ¿òÁý´Ü
  • arterial blood
    µ¿¸ÆÇ÷¾×, µ¿¸ÆÇÇ
  • arterial blood gas
    µ¿¸ÆÇ÷°¡½º
  • arterial blood gas analysis
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • artificial blood
    ÀΰøÇ÷¾×
  • autologous blood
    ÀÚ°¡Ç÷¾×
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • blood flow
    Ç÷·ù
  • blood pressure fluctuation
    Ç÷¾Ðº¯µ¿, Ç÷¾Ð±âº¹
  • arterial blood gas
    µ¿¸ÆÇ÷°¡½º
  • blood grouping
    Ç÷¾×Çü°Ë»ç
  • blood gas
    Ç÷¾×°¡½º
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • blood coagulation mechanism
    Ç÷¾×ÀÀ°í±âÀü
  • blood urea nitrogen
    Ç÷¾×¿ä¼ÒÁú¼Ò
  • blood pressure
    Ç÷¾Ð
  • blood product
    Ç÷¾×Á¦Á¦
  • portal blood pressure
    ¹®¸Æ¾Ð
  • blood flow rate
    Ç÷·ù·®, Ç÷·ù¼Óµµ
  • arterial blood gas study
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • blood sugar
    Ç÷´ç
  • blood supply
    Ç÷¾×°ø±Þ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù
  • group hospital
    º´¿øÁ¶ÇÕ
  • group medicine
    Áý´ÜÁø·á, Çùµ¿Áø·á
  • group practice
    Áý´Ü°³¾÷
  • group psychotherapy
    Áý´ÜÁ¤½Å¿ä¹ý
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢
  • group fascicular repair
    ½Å°æ¼¶À¯´Ù¹ß±ººÀÇÕ(¹ý)
  • group reference value
    Áý´Ü±âÁØÄ¡
  • haptenic group
    ºÒ¿ÏÀüÇ׿ø±º, ÇÕÅÙ±º
  • high risk group
    °íÀ§Çèµµ±º
  • index group
    ÃʹßȯÀÚ±º
  • labile methyl group
    ºÒ¾ÈÁ¤¸ÞÆ¿±â
  • linkage group
    ¿¬°ü±º
  • marathon group
    ¸¶¶óÅæÁý´Ü
  • methyl group
    ¸ÞÆ¿±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • ELBF=£¾effective liver blood flow
    À¯È¿¼º °£Ç÷·ù.
  • ELBF=£¾effective liver blood flow
    À¯È¿ °£Ç÷·ù.
  • Lutheran blood groups
    ·çÅ×¶õÇ÷¾×±º
  • Lutheran s blood groups
    ·çÅ×¶õÇ÷¾×±º.
  • MBP=£¾mean blood pressure
    Áß°£Ç÷¾Ð ¡ìÀÏÀÎÀÇ¡í, Æò±ÕÇ÷¾Ð.
  • Manson blood fluke
    ¸¸¼ÕÇ÷ÈíÃæ
  • OMNISTIK blood gas syringe
    ¿È´Ï½ºÆ½Ç÷¾×°¡½ºÁÖ»ç±â
  • RBC=£¾red blood cell
    ÀûÇ÷±¸.
  • Schaedler blood agar
    ¼¨µé·¯Ç÷¾×ÇÑõ
  • accessory blood vessel
    ºÎÇ÷°ü, Á¾¼ÓÇ÷°ü
  • arterial blood
    µ¿¸ÆÇ÷.
  • arterial blood gas
    µ¿¸ÆÇ÷°¡½º
  • arterial blood gas study
    µ¿¸ÆÇ÷ °¡½ººÐ¼®
  • arterial blood oxygen tension
    µ¿¸ÆÇ÷»ê¼Ò Àå·Â.
  • arterial blood pressure
    µ¿¸ÆÇ÷¾Ð.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • behavioral group therapy
    Áý´ÜÇൿġ·á(¿ä¹ý)
  • borderline group
    °æ°è±º(ÌÑÍ£ÏØ).
  • carbohydrate, group-specfic C
    ±ºÆ¯ÀÌ C ź¼öÈ­¹°
  • coliform group
    ´ëÀå±Õ±º
  • commutative group
    °¡È¯±º(˧̷˴).
  • commutator group
    ±³È¯ÀÚ±º(ÊÙË´).
  • complementation group
    »óº¸¼º Áý´Ü
  • complementophil group
    º¸Ã¼Ä£È­±â.
  • control group
    ´ëÁ¶±º(ÓßðÎÏÛ)
  • control group
    ´ëÁ¶±º(ËÀ̡˴).
  • determinant group
    °áÁ¤±º(¡­ÏØ).
  • diagnosis related group(DRG)
    Áø´Ü¸íº° ±º, À¯»çÇÑ Áø´Ü¸íµé³¢¸® ¹­¾î À̸¦ ´ÜÀ§·Î ÀÇ·áºñ¸¦ ÁöºÒÇÏ´Â ¹æ¹ý
  • diagnostic related group
    Áø´Ü°ü·Ã±º
  • didactic group therapy
    ±³À°Àû Áý´Ü¿ä¹ý
  • directive group therapy
    Áö½Ã¼º Áý´Ü¿ä¹ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • blocking group
    Â÷´Ü±â(ó´Ó¨Ðñ)
  • carbamoyl group
    Ä«¸£¹Ù¸ðÀÏ ±â(Ðñ)
  • carbonyl group
    Ä«¸£º¸´Ò±â(Ðñ)
  • carboxyl group
    Ä«¸£º¹½Ç±â(Ðñ)
  • complementation group
    »óº¸±º(ßÓÜÍÏØ)
  • critical group
    ÀӰ豺(×üÍ£ÏØ)
  • diazo group
    µð¾ÆÁ¶ ±â(Ðñ)
  • diazonium group
    µð¾ÆÁ¶´½ ±â(Ðñ)
  • earthy group
    Å伺±â(÷ÏàõÐñ)
  • end-group analysis
    Á¾´Ü±â ºÐ¼® (ðûÓ®ÐñÝÂà°)
  • fatty acyl group
    Áö¹æ(ò·Û¸) ¾Æ½Ç±â(Ðñ)
  • fidelity group
    Á¤È®µµ ±â(ïáü¬ÓøÐñ)
  • formimino group
    Æ÷¸§À̹̳ë±â(Ðñ)
  • formyl group
    Æ÷¸£¹Ð±â(Ðñ)
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • systemic blood pressure
    üÇ÷¾Ð
  • white blood cell
    ¹éÇ÷±¸
  • whole blood
    ÀüÇ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AGPA American Group Practice Association; American Group Psychotherapy Association
CCG Children's Cancer Study Group; cholecystogram, cholecystography; clinically coherent group
DRG diagnosis-related group; Division of Research Grants [NIH}; dorsal respiratory group; dorsal root ga...
GS gallstone; Gardner syndrome; gastric shield; general surgery; gestational score; Gilbert syndrome; g...
GT gait training; galactosyl transferase; gastrostomy; generation time; genetic therapy; gingiva treatm...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
group 3 group 1
Group 4 group
Group A group 1
group B group A
Group D group
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • black blood imaging
    ÈæÇ÷·ù ¿µ»ó
  • blood
    ÇÇ, Ç÷¾×
    1. ¸Æ°ü°è¸¦ È帣°í ÀÖ´Â ¾×ü·Î ¼¼Æ÷ ¼ººÐÀÎ Ç÷±¸¿Í Ç÷ûÀ¸·Î ±¸¼ºµÈ´Ù. ½ÉÀå ¹× Ç÷°ü Áï ¼øÈ¯°è¸¦ ä¿ì°í ÀÖ´Â ¾×üÀÌ´Ù. 2. ÇÇ, ½ÉÀå, µ¿¸Æ, ¸ð¼¼Ç÷°ü ¹× Á¤¸Æ³»¸¦ ¼øÈ¯Çϸ鼭 ½Åü³» ¼¼Æ÷¿¡ ¿µ¾çºÐ°ú »ê¼Ò¸¦ ¿î¹ÝÇÏ´Â ¾×üÀ̸ç, ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇ µîÀ» Æ÷ÇÔÇÑ À¯Çü ¼ººÐ°ú Ç÷ÀåÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. 3. ²öÀû²öÀûÇÑ ¾×ü·Î¼­, ÀûÇ÷±¸ÀÇ Ç÷»ö¼Ò ?¹®¿¡ ¼±È«»öÀ» ¶è´Ù. 4. Ç÷°ü ¼ÓÀ» È帣°í ÀÖ´Â ¾×»óÀÇ Á¶Á÷. ¼±¸íÇÑ Àû»öÀ» ¶ì°í ÀÖ°í ºÒÅõ¸íÇÏ¸ç ±ÕÀÏÇÏ°Ô º¸ÀδÙ. ±×·¯³ª Ç÷¾×ÀÇ ÀÛÀº ¹æ¿ïÀ» À¯¸®ÆÇ¿¡ ¾ã°Ô Æì°í Çö¹Ì°æÀ¸·Î º¸¸é Åõ¸íÇÑ ¾×ü ¼Ó¿¡ Ç÷±¸°¡ ºÎÀ¯Çϰí ÀÖ¾î ±ÕÀÏÇÏÁö ¾ÊÀ½À» ¾Ë ¼ö ÀÖ´Ù. Ç÷¾×ÀÇ ÁÖµÈ ¿ªÇÒÀº °¢Á¾ ¹°ÁúÀÇ ¿î¹ÝÀ̸ç, Æó¿¡¼­ ¼·ÃëÇÑ »ê¼Ò³ª ¼ÒÈ­°ü¿¡¼­ Èí¼öÇÑ ¿µ¾ç¼Ò µîÀ» Àü½ÅÀÇ ¸ðµç ¼¼Æ÷·Î º¸³»°í ¹Ý´ë·Î ¼¼Æ÷¿¡¼­ ¸¸µé¾îÁø ź»ê°¡½º³ª ³ëÆó¹°À» ¿î¹ÝÇØ¼­ Æó, ½ÅÀå, ÇǺΠµîÀ» ÅëÇØ¼­ ¸ö¹ÛÀ¸·Î ¹è¼³ÇÑ´Ù. ¶Ç °ñ°Ý±ÙÀ̳ª °£°ú °°ÀÌ ¿­ »ý»êÀÌ ¿Õ¼ºÇÑ °÷À¸·ÎºÎÅÍ ´Ù¸¥ ºÎºÐÀ¸·Î ¿­À» ¿Å°Ü¼­ ü¿­ÀÇ ºÐÆ÷¸¦ ±ÕµîÇÏ°Ô Çϰí, ÇǺο¡¼­ ¹æ¿­ÇÏ¿© ü¿ÂÀ» ÀÏÁ¤ÇÏ°Ô À¯Áö½ÃŰ´Â µ¥µµ °ü¿©ÇÑ´Ù. Ç÷¾×·®Àº üÁßÀÇ ¾à 8 %, ºñÁßÀº 1.06À̹ǷΠüÁßÀÌ 60 kgÀÎ ¶§ ¾à 4.5§¤°¡ µÈ´Ù. Ç÷¾×·®Àº °ÅÀÇ ÀÏÁ¤Çؼ­ ¾×ü¸¦ ¼·ÃëÇßÀ» ¶§³ª ÀûÀº ¾çÀÇ ÃâÇ÷ÀÌ ÀÖÀ» ¶§µµ Ç÷°ü ¼ÓÀÇ ¼øÈ¯ Ç÷¾×·®À» ÀÚÀ²ÀûÀ¸·Î Á¶ÀýÇÏ¿© Àüü Ç÷¾×·®Àº º¯ÇÏÁö ¾Ê´Â´Ù. ÇÑÆí, ´ë·®ÀÇ ¹°À» ¸¶¼ÌÀ» ¶§ ¼öºÐÀº °ð Ç÷¾×¿¡¼­ Á¶Á÷À¸·Î ³ª°¡°Å³ª ½ÅÀåÀ¸·ÎºÎÅÍ ¹è¼³µÈ´Ù. Ç÷¾×ÀÇ Á¡Á¶µµ´Â ¹°ÀÇ ¾à 5¹èÀ̰í, ÁÖ·Î Ç÷±¸ ¼ö¿¡ µû¶ó º¯ÇÑ´Ù. ºóÇ÷ÀÏ ¶§Ã³·³ ÀûÇ÷±¸°¡ °¨¼ÒÇϸé Á¡Á¶µµ°¡ ³·¾ÆÁ®¼­ Ç÷¾×ÀÌ Ç÷°ü ³»¸¦ È带 ¶§ ÀúÇ×ÀÌ °¨¼ÒµÇ¹Ç·Î Ç÷¾ÐÀÌ ¶³¾îÁø´Ù. µû¶ó¼­ Ç÷¾×ÀÇ Á¡Á¶µµ°¡ Ç÷¾ÐÀ» À¯ÁöÇÏ´Â µ¥¿¡ Áß¿äÇÑ ±¸½ÇÀ» Çϰí ÀÖÀ½À» ¾Ë ¼ö ÀÖ´Ù. Ç÷¾×ÀÇ »ïÅõ¾ÐÀº 6.7±â¾ÐÀ¸·Î 0.9 %ÀÇ ½Ä¿°¼ö¿Í °°´Ù. ¸¸¾à Ç÷¾×º¸´Ù ³·Àº »ïÅõ¾ÐÀÇ ½Ä¿°¼ö¿¡ Ç÷¾×À» ³ÖÀ¸¸é Ç÷±¸ ¼Ó¿¡ ¼öºÐÀÌ »¡·Á µé¾î°¡ ºÎÇ®¾î ¸¶Ä§³»´Â ÆÄ±«µÈ´Ù. À̰ÍÀ» ¿ëÇ÷À̶ó°í ÇÑ´Ù. ¶Ç ¹Ý´ë·Î Ç÷¾×º¸´Ù ³ôÀº »ïÅõ¾ÐÀÇ ½Ä¿°¼ö ¾È¿¡¼­´Â Ç÷±¸ ¼ÓÀÇ ¼öºÐÀÌ ¹ÛÀ¸·Î ³ª¿Í Ç÷±¸´Â ¿À±×¶óµé°í ¸¸´Ù. ±×¸®°í Ç÷¾×°ú °°Àº »ïÅõ¾ÐÀÇ ½Ä¿°¼ö¸¦ »ý¸®Àû ½Ä¿°¼ö¶ó ÇÑ´Ù. Ç÷¾×ÀÇ
  • blood agar
    Ç÷¾× ÇÑõ
  • blood alcohol level
    Ç÷Áß ¾ËÄÚ¿Ã ³óµµ
  • blood blister
    ¼ÒÇ÷Á¾
    Ç÷¾×¼º ³»¿ë¹°À» °¡Áø ÀÛÀº ¼öÆ÷·Î¼­ ²¿ÁýÈ÷°Å³ª Ÿ¹Ú»óÀ¸·Î »ý±âÁö¸¸ °¡²û Áö¼ÓÀûÀÎ ¸¶Âû¿¡ ÀÇÇØ¼­µµ »ý±ä´Ù.
  • blood capillary
    ¸ð¼¼Ç÷°ü
    ¼Òµ¿¸Æ°ú ¼ÒÁ¤¸ÆÀ» ¿¬°áÇÏ´Â ¹Ì¼¼ÇÑ Ç÷°ü. ÀÌ º®Àº Ç÷¾×°ú Á¶Á÷¾×ÀÇ ¿©·Á ¹°ÁúÀ» ±³È¯Çϱâ À§ÇÑ ¹ÝÅõ¸·À¸·Î ÀÛ¿ëÇÑ´Ù.
  • blood cell counter
    Ç÷±¸ °è¼ö±â
  • blood center
    Ç÷¾×¿ø
    µ¿ÀǾî=blood transfusion service. ¼öÇ÷¿¡ ÇÊ¿äÇÑ Ç÷¾×À» äÇ÷, Á¶Á¦, º¸Á¸ÇÏ°í °ø±ÞÇÏ´Â ±â°ü. 1937³â ¹Ì±¹ ½ÃÄ«°íÀÇ ÄîÄ«¿îƼ
  • blood cerebrospinal fluid barrier
    Ç÷³ú ô¼ö¾× À庮, Ç÷¾× ³úô¼ö¾× °ü¹®
  • blood circulation
    Ç÷¾× ¼øÈ¯
    Á½ɽǿ¡¼­ µ¿¸ÆÀ¸·Î ¾ÐÃâµÈ Ç÷¾×Àº ¸ð¼¼Ç÷°üÀ» °ÅÃļ­ Á¤¸ÆÀ¸·Î ³ª¿À°í ¿ì½É¹æÀ¸·Î ȯ·ùÇØ À̰÷¿¡¼­ ¿ì½É½Ç·Î µé¾î°£´Ù. ¿ì½É½ÇÀÇ ¼öÃàÀ¸·Î Æóµ¿¸ÆÀ¸·Î º¸³»Á® Æó ¸ð¼¼°üÀ» °ÅÃļ­ Æó Á¤¸Æ¿¡¼­ Á½ɹæÀ¸·Î µé¾î°¡°í ´Ù½Ã Á½ɽǷΠµé¾î°¡ ¸ö ¾ÈÀ» ÇѹÙÄû µ·´Ù.
  • blood clotting disturbance
    Ç÷¾× ÀÀ°í Àå¾Ö
  • blood coagulation
    Ç÷¾× ÀÀ°í
    µ¿ÀǾî=blood clotting. 1. Ç÷¾×ÀÇ ¸¹Àº ÀÀ°íÀÎÀÚ°¡ »óÈ£ÀÛ¿ëÇϰí ÇÕÃÄÁ®¼­ ÃÖÈÄ¿¡´Â ºÒ¿ë¼ºÀÇ ¼¶À¯¼Ò ±«ÀÇ Çü¼ºÀ» ÀÏÀ¸Å°´Â ¿¬¼ÓÀû ¹ÝÀÀÀÌ´Ù. 2. Ç÷¾×ÀÌ Ç÷°ü ¹ÛÀ¸·Î ³ª¿ÔÀ» ¶§ Á©¸®»óÀ¸·Î ±»¾îÁö´Â Çö»ó. À̰ÍÀº Ç÷¾× ¼Ó¿¡ ÇǺ기À̶ó°í ÇÏ´Â ½Ç ¸ð¾çÀÇ ¹°ÁúÀÌ ¼®ÃâµÇ¾î ±×¹° ¸ð¾çÀ¸·Î ¾ôÈ÷°í, ±× ¼Ó¿¡ Ç÷±¸¸¦ °¡µÎ¾î µÎ±â ¶§¹®ÀÌ´Ù. ÀÌ Ç÷±¸ µ¢¾î¸®´Â ½Ã°£ÀÌ Áö³²¿¡ µû¶ó Á¡Á¡ ¼öÃàÇÏ¿© ÀÛ¾ÆÁö¸é¼­ ´ãȲ»öÀÇ Åõ¸íÇÑ ¾×ü°¡ ½º¸ç ³ª¿Â´Ù. Ç÷±¸ÀÇ µ¢¾î¸®¸¦ Ç÷º´À̶ó Çϰí, ½º¸ç ³ª¿Â Åõ¸íÇÑ ¾×ü¸¦ Ç÷ûÀ̶ó°í ÇÑ´Ù. Ç÷¾× ÀÀ°í´Â »ý¸íÀ» À¯ÁöÇÏ´Â µ¥ ºÒ°¡°áÇÑ °ÍÀ¸·Î, ¸¸ÀÏ Ç÷¾×¿¡ ÀÌ ÀÛ¿ëÀÌ ¾øÀ¸¸é ÃâÇ÷¿¡ ÀÇÇÏ¿© °ð Á×°Ô µÈ´Ù. ÀÏ»ó»ýȰ¿¡¼­´Â ²÷ÀÓ¾øÀÌ ¿Ü»óÀ» ÀÔ°Ô µÇ°í ±×¶§ ´Ù¼Ò³ª¸¶ ¸ð¼¼Ç÷°üÀÌ ÆÄ¿­µÇ´Âµ¥, ÆÄ¼ÕºÎÀ§´Â Ç÷¾× ÀÀ°í¿¡ ÀÇÇÏ¿© ¼öº¹µÈ´Ù. Ç÷¾× ÀÀ°í°¡ ÀϾ´Â ¸ÞÄ¿´ÏÁò¿¡ ´ëÇØ¼­´Â ¸î °¡Áö ¼³ÀÌ ÀÖÁö¸¸ ¾î´À °ÍÀÌµç ±âº»ÀûÀ¸·Î´Â Ç÷¾×ÀÌ Ç÷°ü ¹ÛÀ¸·Î ³ª¿À¸é Ç÷¼ÒÆÇÀÌ ÆÄ±«µÇ¾î Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ »ý±â°í, À̰ÍÀÌ Ç÷¾× ¼ÓÀÇ Ä®½· À̿°ú ÇÔ²² ÀÛ¿ëÇÏ¿© Ç÷Àå ´Ü¹éÁúÀÇ ÇϳªÀÎ ÇÁ·ÎÆ®·ÒºóÀ» Æ®·ÒºóÀ¸·Î º¯È­½ÃŲ´Ù. ÀÌ Æ®·ÒºóÀÌ ÇǺ긮³ë°Õ¿¡ ÀÛ¿ëÇÏ¿© ÇǺ기ÀÌ µÈ´Ù. ÀÌ °úÁ¤¿¡´Â Ç÷ÀåÀ̳ª Ç÷¼ÒÆÇ¿¡ ÀÖ´Â ¸¹Àº ÀÎÀÚ°¡ °ü¿©Çϴµ¥, ¿¬±¸ÀÚ¿¡ µû¶ó °¢¾ç°¢»öÀÇ À̸§À¸·Î ºÒ¸®¾î È¥¶õÀ» ÃÊ·¡Çϰí ÀÖÀ¸¹Ç·Î, ±¹Á¦Ç÷¾×ÀÀ°íÀ§¿øÈ¸¿¡¼­ À̵é ÀÎÀÚ¸¦ ¹øÈ£·Î ³ªÅ¸³»µµ·Ï °áÁ¤Çϰí ÀÖ´Ù. Á¦1»óÀÇ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ Çü¼ºµÇ´Â °úÁ¤ÀÌ °¡Àå º¹ÀâÇϰí, Ç÷¾× ÀÀ°í¿¡ °É¸®´Â ´ëºÎºÐÀÇ ½Ã°£ÀÌ ÀÌ °úÁ¤¿¡ ¼Ò¿äµÈ´Ù. Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ ¸¸µé¾îÁö´Â µ¥´Â µÎ °¡Áö °æ·Î°¡ ÀÖ´Ù. óÀ½ °æ·Î´Â Ç÷°ü ¼Ó¿¡¼­ ÀÌ·ç¾îÁø´Ù. Ç÷Àå ¼Ó¿¡ À̹°Áú°ú Á¢Çϸé Ȱ¼ºÈ­µÇ´Â È¿¼Ò°¡ Àִµ¥, ÇöÀç Á¦ XIÀÎÀÚ¿Í Á¦ XIIÀÎÀÚÀÇ µÎ °¡Áö°¡ ¾Ë·ÁÁ® ÀÖ´Ù. À̰ÍÀÌ ¹æ¾Æ¼è°¡ µÇ¾î Á¦ VÀÎÀÚ, Á¦ VIIIÀÎÀÚ, Á¦ IXÀÎÀÚ µî°ú Ç÷¼ÒÆÇÀ¸·ÎºÎÅÍÀÇ ÀÎÀÚ°¡ ÀÛ¿ëÇÏ¿© Ç÷¾× Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ »ý¼ºµÈ´Ù. ´Ù¸¥ ÇϳªÀÇ °æ·Î´Â Ç÷°ü ¹ÛÀÇ Á¶Á÷¿¡¼­ ÀÌ·ç¾îÁø´Ù. ÆÄ±«µÈ Á¶Á÷¿¡ Ç÷Àå ¼ÓÀÇ Á¦ VÀÎÀÚ, Á¦ VIIÀÎÀÚ, Á¦ XÀÎÀÚ µîÀÌ ÀÛ¿ëÇÏ¿© Á¶Á÷ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ »ý¼ºµÈ´Ù. Á¦2»óÀÇ Æ®·ÒºóÀÇ »ý¼º¿¡¼­´Â Ç÷¾× ¹× Á¶Á÷¿¡ »ý±ä Ȱ¼º Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ Ä®½· À̿°ú ÇÔ²² Ç÷Àå ¼ÓÀÇ ÇÁ·ÎÆ®·Òºó¿¡ ÀÛ¿ëÇÏ¿© Æ®·ÒºóÀ» Çü¼ºÇÑ´Ù. ÇÁ·ÎÆ®·ÒºóÀº °£¿¡¼­ ºñŸ¹Î KÀÇ ÀÛ¿ëÇÏ¿¡ ¸¸µé¾îÁö°í, ÇìÆÄ¸°Àº ÀÌ Á¦ 2»óÀ» ¾ïÁ¦ÇÏ¿© Ç÷¾× ÀÀ°í ÀúÁö ÀÛ¿ëÀ» ³ªÅ¸³½´Ù. Á¦ 3»ó¿¡¼­´Â Æ®·ÒºóÀÌ ÇǺ긮³ë°ÕÀÇ ÆéƼµå °áÇÕÀ» ºÐÇØÇÏ¿© ÇǺ기 ¼¶À¯¸¦ ¼®Ãâ½ÃŲ´Ù. ¿©±â¿¡ Ä®½· À̿°ú ÇÔ²² Á¦ XIII ÀÎÀÚ°¡ ÀÛ¿ëÇÏ¿© ÇǺ기¸ÁÀ» ¸¸µé¾î Ç÷º´ÀÌ ¿Ï¼ºµÈ´Ù. ¿©±â¿¡¼­ »ý¼ºµÈ ÇǺ기Àº ±×´ë·Î µÎ¸é ´Ù½Ã ¿ëÇØµÇ´Âµ¥ À̰ÍÀ» ¼¶À¯¼Ò ¿ëÇØ¶ó°í ÇÑ´Ù. ÀÌ ¼¶À¯¼Ò ¿ëÇØ´Â Ç÷Àå ¼Ó¿¡ ÀÖ´Â Çö󽺹̳ë°ÕÀÌ È°¼ºÈ­ÇÏ¿© Çö󽺹ÎÀÌ µÇ°í ÇǺ기À» ³ìÀ̱⠶§¹®ÀÌ´Ù.
  • blood compatibility testing
    Ç÷¾× ÀûÇÕ¼º °Ë»ç
  • blood concentration
    Ç÷Áß ³óµµ
  • blood count
    Ç÷±¸°è»ê
    ÀÏÁ¤ÀÇ Ç÷¾×·® 1§§Áß À¯Çü ¼ººÐ¼öÀÇ ÃøÁ¤.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
antigens, CD <immunology> Differentiation antigens residing on human leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similiar reactivity with certain subpopulations of antigens. The subpopulations of antigens are also known by the same CD designation.
(12 Dec 1998)
antigens, CD1 <immunology> Glycoproteins expressed on cortical thymocytes and on some dendritic cells and B-cells. Their structure is similar to that of MHC class I and their function has been postulated as similar also. Cd1 antigens are highly specific markers for human langerhans cells.
(12 Dec 1998)
antigens, CD11 <immunology> A group of three different alpha chains (CD11a, CD11b, CD11c) that are associated with an invariant CD18 beta chain (antigens, CD18). The three resulting leukocyte-adhesion molecules (receptors, leukocyte adhesion) are lymphocyte function-associated antigen-1, macrophage-1 antigen, and antigen, p150,95.
(12 Dec 1998)
antigens, CD13 <enzyme, immunology> Glycoproteins expressed on human granulocyte-monocyte progenitor colony forming units (cfu-gm) and their more differentiated progeny. The enzymes are also found in a large number of tissues, often associated with membranes.
Registry number: EC 3.4.11.2
(12 Dec 1998)
antigens, CD14 <immunology> Glycolipid-anchored membrane glycoproteins expressed on cells of the myelomonocyte lineage including monocytes, macrophages, and some granulocytes. They function as receptors for the complex of lipopolysaccharide (lps) and lps-binding protein.
(12 Dec 1998)
antigens, CD15 <immunology> Carbohydrate antigen which is accumulated in various human cancer tissues and secreted into the blood stream. The carbohydrate moiety can be further modified with fucose or sialic acid. Monoclonal antibodies have been determined which can discriminate each subgroup of this antigen in the sera of cancer patients. Sialyl ssea-1 antigen is particularly elevated in the sera of patients with a variety of tumours.
(12 Dec 1998)
antigens, CD18 <immunology> Cell-surface glycoprotein beta-chains that are non-covalently linked to specific alpha-chains of the CD11 family of leukocyte-adhesion molecules (receptors, leukocyte-adhesion). A defect in the gene encoding CD18 causes leukocyte-adhesion deficiency syndrome.
(12 Dec 1998)
antigens, CD19 <immunology> Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
(12 Dec 1998)
antigens, CD2 <immunology> Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.
(12 Dec 1998)
antigens, CD20 <immunology> Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane calcium conductance and thought to play a role in B-cell activation and proliferation.
(12 Dec 1998)
antigens, CD26 <enzyme, immunology> Cell-surface glycoproteins and serine protease, also known as dipeptidyl-peptidase IV, that play a role in t-lymphocyte activation. Cd26 binds to adenosine deaminase on the T-cell surface.
Registry number: EC 3.4.14.5
(12 Dec 1998)
antigens, CD27 <immunology> Dimeric membrane glycoproteins found on most T-lymphocytes. Activation of T-cells by the antigen receptor increases CD27 surface expression.
(12 Dec 1998)
antigens, CD28 <immunology> T-cell differentiation antigens that serve as the receptors for the b7 antigen (antigens, CD80) which modulates T-cell lymphokine production.
(12 Dec 1998)
antigens, CD29 <immunology> Integrin beta-1 chains which are expresssed as heterodimers noncovalently associated with specific alpha-chains of the CD49 family (CD49a-f). Cd29 is expressed on resting and activated leukocytes and is a marker for total very late activation antigens on cells. (barclay et al., the leukocyte antigen factsbook, 1993, p164)
(12 Dec 1998)
antigens, CD3 <immunology> A complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (receptors, antigen, T-cell). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (receptors, antigen, T-cell, gamma-delta).
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • new blood
    (»õ·Î¿î Ȱ·Â(»ç»ó)ÀÇ ¿øÃµÀ¸·Î¼­ÀÇ)ÀþÀºÀ̵é;½ÅÀεé
  • red blood cell(corpuscle)
    ÀûÇ÷±¸
  • young blood
    ûÃáÀÇ Ç÷±â;ÀþÀºÀ̵é
  • age-group
    ¿¬·É Áý´Ü
  • group
    Áý´Ü,¶¼¸¦ Áþ´Ù,ºÐ·ùÇÏ´Ù
  • Group of 77
    77°³±¹ ±×·ì(UNÀÇ ¹«¿ª°³¹ß ȸÀÇ(UNCTAD)ÀÇ È¸¿øÀÎ ¹ßÀü µµ»ó±¹ ±×·ì)
  • Group of Seven
    G;7 ¼±Áø 7°³±¹ ±×·ì
  • code group
    ºÎÈ£±º
  • continuous group
    ¿¬¼Ó±º
  • control group
    Á¦¾îÁý´Ü;Á¶Á¾ÀåÄ¡;´ëÁ¶±º(µ¿ÀϽÇÇè¿¡¼­ ½ÇÇè¿ä°ÇÀ» °¡ÇÏÁö ¾ÊÀº ±×·ì)
  • enxounter group
    (Á¤ÀÇ)Áý´Ü °¨¼ö¼º ÈÆ·Ã ±×·ì
  • ethnic group
    (»çȸ)ÀÎÁ¾ Áý´Ü
  • focus group
    Æ÷Ä¿½º ±×·ì(Å×½ºÆ®ÇÒ »óǰ¿¡ ´ëÇØ¼­ ÅäÀÇÇÏ´Â ¼ÒºñÀÚ ±×·ì)
  • fringe group
    ºñÁÖ·ùÆÄ
  • front group
    (À§ÀåÇÑ) Ç¥¸é»óÀÇ Á¶Á÷(´Üü)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á